These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9020935)

  • 1. Gene therapy for HIV infection.
    Morgan RA
    Clin Exp Immunol; 1997 Jan; 107 Suppl 1():41-4. PubMed ID: 9020935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
    Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
    Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
    Mautino MR; Morgan RA
    Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
    BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
    J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 Tat transactivator protein: a therapeutic target?
    Fulcher AJ; Jans DA
    IUBMB Life; 2003 Dec; 55(12):669-80. PubMed ID: 14769003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress towards gene therapy for HIV infection.
    Yu M; Poeschla E; Wong-Staal F
    Gene Ther; 1994 Jan; 1(1):13-26. PubMed ID: 7584055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells.
    Liu J; Woffendin C; Yang ZY; Nabel GJ
    Gene Ther; 1994 Jan; 1(1):32-7. PubMed ID: 7584057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
    Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
    Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
    Mautino MR; Keiser N; Morgan RA
    J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen.
    Fanning G; Amado R; Symonds G
    J Gene Med; 2003 Aug; 5(8):645-53. PubMed ID: 12898634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HIV effects of HIV vectors.
    Corbeau P; Wong-Staal F
    Virology; 1998 Apr; 243(2):268-74. PubMed ID: 9568026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
    Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
    Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
    Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
    Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy clinical trials for HIV.
    Statham S; Morgan RA
    Curr Opin Mol Ther; 1999 Aug; 1(4):430-6. PubMed ID: 11713756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: StealthVector (HIV) Enzo.
    Günzburg W; Mhashilkar AM; Hindi M
    Curr Opin Mol Ther; 1999 Oct; 1(5):651-7. PubMed ID: 11249672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication.
    Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J
    Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.
    Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL
    Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
    Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Fanning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray J; Gerlach W; Sun LQ; Penny R; Symonds GP; Carr A; Cooper DA
    J Gene Med; 2005 May; 7(5):552-64. PubMed ID: 15655805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of a triple combination gene therapy vector inhibiting HIV-1 multiplication.
    Asparuhova MB; Barde I; Trono D; Schranz K; Schümperli D
    J Gene Med; 2008 Oct; 10(10):1059-70. PubMed ID: 18642399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of HTLV-I gene expression by HIV-1 Rev through an alternative RxRE-independent pathway mediated by the RU5 portion of the 5'-LTR.
    Kubota S; Furuta RA; Hatanaka M; Pomerantz RJ
    Biochem Biophys Res Commun; 1998 Feb; 243(1):79-85. PubMed ID: 9473483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.